Metamark has for the first time, presented results the clinical validation study that showed ProMark, the first proteomic-based imaging biopsy test. ProMark was shown to predict which patients have low-risk disease with a sensitivity of 90 percent or better, confidently identifying patients who are appropriate for active surveillance or need aggressive therapy. The data is being presented at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). "These ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1jZEXnE
No comments:
Post a Comment